Cargando…

Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial

The activity and mild toxicity profile of single-agent gemcitabine therapy in untreated (chemonaive) patients with non-small-cell lung cancer (NSCLC) is well documented. This phase II trial was conducted to determine the objective tumour response rate and toxicity profile of single-agent gemcitabine...

Descripción completa

Detalles Bibliográficos
Autores principales: Kooten, M Van, Traine, G, Cinat, G, Cazap, E, Comba, A Zori, Vicente, H, Sena, S, Nievas, O Rodriguez, Orlando, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374290/
https://www.ncbi.nlm.nih.gov/pubmed/10555756
http://dx.doi.org/10.1038/sj.bjc.6690774
_version_ 1782154418308775936
author Kooten, M Van
Traine, G
Cinat, G
Cazap, E
Comba, A Zori
Vicente, H
Sena, S
Nievas, O Rodriguez
Orlando, M
author_facet Kooten, M Van
Traine, G
Cinat, G
Cazap, E
Comba, A Zori
Vicente, H
Sena, S
Nievas, O Rodriguez
Orlando, M
author_sort Kooten, M Van
collection PubMed
description The activity and mild toxicity profile of single-agent gemcitabine therapy in untreated (chemonaive) patients with non-small-cell lung cancer (NSCLC) is well documented. This phase II trial was conducted to determine the objective tumour response rate and toxicity profile of single-agent gemcitabine in pretreated patients with NSCLC. Patients with histological evidence of advanced NCSLC stage IIIB or IV; at least one prior chemotherapy regimen including a platinum or taxane analogue; an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2; clinically measurable disease; adequate bone marrow reserve; and adequate renal function; received 1000 mg m(–2) gemcitabine administered over 30 min on days 1, 8 and 15 of a 28-day cycle defined as 3 weekly treatments followed by 1 week of rest. Twenty-nine patients were evaluated for efficacy and 32 for toxicity. One patient achieved a complete response and five patients had a partial response resulting in a total response rate of 20.6% (95% confidence interval (CI) 6–34). Median response duration was 7 months (range 4–11 months). Twelve (41%) patients reached stable disease after two cycles of therapy and 11 (38%) patients had disease progression. Median progression-free survival time was 3 months and median overall survival time was 5.5 months. Toxicity was generally mild (grades 0–2). Severe (grade 3 or 4) haematological toxicities included grade 3 anaemia in one patient and grade 3 thrombocytopenia in two patients. Severe non-haematological toxicities included one patient each with grade 3 liver transaminase elevations, nausea/vomiting and diarrhoea. This study confirms the activity and safety of single-agent gemcitabine in pretreated patients with advanced NSCLC who are refractory or sensitive to first-line therapy. © 1999 Cancer Research Campaign
format Text
id pubmed-2374290
institution National Center for Biotechnology Information
language English
publishDate 1999
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23742902009-09-10 Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial Kooten, M Van Traine, G Cinat, G Cazap, E Comba, A Zori Vicente, H Sena, S Nievas, O Rodriguez Orlando, M Br J Cancer Regular Article The activity and mild toxicity profile of single-agent gemcitabine therapy in untreated (chemonaive) patients with non-small-cell lung cancer (NSCLC) is well documented. This phase II trial was conducted to determine the objective tumour response rate and toxicity profile of single-agent gemcitabine in pretreated patients with NSCLC. Patients with histological evidence of advanced NCSLC stage IIIB or IV; at least one prior chemotherapy regimen including a platinum or taxane analogue; an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2; clinically measurable disease; adequate bone marrow reserve; and adequate renal function; received 1000 mg m(–2) gemcitabine administered over 30 min on days 1, 8 and 15 of a 28-day cycle defined as 3 weekly treatments followed by 1 week of rest. Twenty-nine patients were evaluated for efficacy and 32 for toxicity. One patient achieved a complete response and five patients had a partial response resulting in a total response rate of 20.6% (95% confidence interval (CI) 6–34). Median response duration was 7 months (range 4–11 months). Twelve (41%) patients reached stable disease after two cycles of therapy and 11 (38%) patients had disease progression. Median progression-free survival time was 3 months and median overall survival time was 5.5 months. Toxicity was generally mild (grades 0–2). Severe (grade 3 or 4) haematological toxicities included grade 3 anaemia in one patient and grade 3 thrombocytopenia in two patients. Severe non-haematological toxicities included one patient each with grade 3 liver transaminase elevations, nausea/vomiting and diarrhoea. This study confirms the activity and safety of single-agent gemcitabine in pretreated patients with advanced NSCLC who are refractory or sensitive to first-line therapy. © 1999 Cancer Research Campaign Nature Publishing Group 1999-11 /pmc/articles/PMC2374290/ /pubmed/10555756 http://dx.doi.org/10.1038/sj.bjc.6690774 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Kooten, M Van
Traine, G
Cinat, G
Cazap, E
Comba, A Zori
Vicente, H
Sena, S
Nievas, O Rodriguez
Orlando, M
Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial
title Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial
title_full Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial
title_fullStr Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial
title_full_unstemmed Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial
title_short Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial
title_sort single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an argentinean multicentre phase ii trial
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374290/
https://www.ncbi.nlm.nih.gov/pubmed/10555756
http://dx.doi.org/10.1038/sj.bjc.6690774
work_keys_str_mv AT kootenmvan singleagentgemcitabineinpretreatedpatientswithnonsmallcelllungcancerresultsofanargentineanmulticentrephaseiitrial
AT traineg singleagentgemcitabineinpretreatedpatientswithnonsmallcelllungcancerresultsofanargentineanmulticentrephaseiitrial
AT cinatg singleagentgemcitabineinpretreatedpatientswithnonsmallcelllungcancerresultsofanargentineanmulticentrephaseiitrial
AT cazape singleagentgemcitabineinpretreatedpatientswithnonsmallcelllungcancerresultsofanargentineanmulticentrephaseiitrial
AT combaazori singleagentgemcitabineinpretreatedpatientswithnonsmallcelllungcancerresultsofanargentineanmulticentrephaseiitrial
AT vicenteh singleagentgemcitabineinpretreatedpatientswithnonsmallcelllungcancerresultsofanargentineanmulticentrephaseiitrial
AT senas singleagentgemcitabineinpretreatedpatientswithnonsmallcelllungcancerresultsofanargentineanmulticentrephaseiitrial
AT nievasorodriguez singleagentgemcitabineinpretreatedpatientswithnonsmallcelllungcancerresultsofanargentineanmulticentrephaseiitrial
AT orlandom singleagentgemcitabineinpretreatedpatientswithnonsmallcelllungcancerresultsofanargentineanmulticentrephaseiitrial